No profile data available.
CervoMed Inc. (CRVO) is a healthcare company in the brain and nerve treatment drugs industry, based in Boston, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$26.97 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $48.68 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
CervoMed reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$48.68 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Mira Pharmaceuticals, Inc. (MIRA), Alterity Therapeutics Limited (ATHE), Annovis Bio, Inc. (ANVS), Incannex Healthcare Inc. (IXHL).